Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis

Abstract

This study analyzes data from the open clinical trial GLIMPSE comparing the efficacy of cladribine in tablets (n=633) in comparison with fingolimod (n=1195), dimethyl fumarate (n=912), and teriflunomide (n=735) in remitting multiple sclerosis (MS) in real clinical practice. Cladribine tablets have demonstrated significantly higher efficacy compared to fingolimod, teriflunomides and dimethyl fumarate. This indicates the need for more active use of cladribine in tablets with active forms of MS.